Probiotics for Prophylaxis and Management of Breast Cancer: Preclinical and Clinical Evidence

Ranjbar, Sheyda; Seyednejad, Seyed Afshin; Zakeri, Shahab Edalatian; Rezaeizadeh, Hossein; Rahimi, Roja

doi:10.1007/978-981-15-8214-1_8

Cited by 5 publications

(6 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, Alistipes sp._2, Alistipes sp._3 and Rikenellaceae bacterium_2 were enriched in the fecal microbiota of the probiotic group. Indeed, Alistipes is a genus of the Rikenellaceae family, and it is also a known SCFA-producing genus in the gut [ 48 ]. An increased abundance of Alistipes was observed in probiotic-treated hepatocellular carcinoma-bearing mice; this genus could exert tumor suppressive effect via producing anti-inflammatory metabolites together with other gut microbes [ 49 ], and it protected against conditions such as colitis and liver fibrosis [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

Lacticaseibacillus rhamnosus Probio-M9-Driven Mouse Mammary Tumor-Inhibitory Effect Is Accompanied by Modulation of Host Gut Microbiota, Immunity, and Serum Metabolome

Zhang

et al. 2022

Nutrients

View full text Add to dashboard Cite

Gut microbiome may influence tumor growth and cancer treatment efficacy, so it is a potential target for tumor prevention/treatment. This pilot study investigated the preventive and therapeutic effects of a probiotic strain, Lacticaseibacillus rhamnosus Probio-M9 (Probio-M9), against murine mammary cancer. Thirty-six female mice were randomly divided into three groups (n = 12 per group): control (without tumor transplantation), model (tumor transplantation; no probiotic administration), and probiotic (30-day oral gavage of probiotic, started seven days before tumor transplantation). Changes in tumor size were recorded, and blood, tumor tissue, and stool samples were collected at the end of the trial for analyses. Comparing with the model group, the probiotic group had a significantly smaller tumor volume (p < 0.05), a higher fecal microbiota Shannon diversity index, with significant modifications in the gut microbiota structure (p < 0.05), characterized by more Alistipes sp._2, Porphyromonadaceae bacterium_7, and Bacteroidales bacterium 55_9 (p < 0.05). Additionally, Probio-M9 administration elevated the serum IFN-γ, IL-9, IL-13, and IL-27 levels and several metabolites (e.g., pyridoxal, nicotinic acid, 3-hydroxybutyric acid, glutamine; p < 0.05), while reducing IL-5 (p < 0.05). These changes might be associated with the protective effect of Probio-M9 against mammary tumor growth. Thus, probiotic administration could harness host gut microbiome in anti-cancer responses.

show abstract

Section: Discussionmentioning

confidence: 99%

Lacticaseibacillus rhamnosus Probio-M9-Driven Mouse Mammary Tumor-Inhibitory Effect Is Accompanied by Modulation of Host Gut Microbiota, Immunity, and Serum Metabolome

Zhang

et al. 2022

Nutrients

View full text Add to dashboard Cite

show abstract

“…Our results of principal coordinate analysis showed that the gut microbiota structure of the probiotic group differed from that of the model group, suggesting that probiotic administration was related to changes in the gut microbiota structure of tumor-bearing mice. Ranjbar et al (2021) described dysregulated changes in the gut microbiota composition and function through immune-and estrogenmediated pathways in breast cancer subjects, and concluded that the gut microbiota plays a major role in the development of breast cancer (Ranjbar et al, 2021). Moreover, the study of Plaza-Díaz et al (2019) concluded that women with breast cancer had obviously different microbiota pattern compared with healthy individuals, not only in terms of taxonomic diversity and distribution but also their encoded functionality, such as metabolic capacity and DNA repairing capacity (Plaza-Díaz et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Lacticaseibacillus rhamnosus Probio-M9-driven mouse mammary tumor-inhibitory effect is accompanied by modulation of host gut microbiota, immunity, and serum metabolome

Kwok

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

Breast cancer is one of the most common cancers in women. Gut microbiome may influence tumor growth and the outcome of cancer treatment, so it may be considered as a target for tumor prevention and treatment. This study investigated the preventive and therapeutic effects of the probiotic strain, Lacticaseibacillus rhamnosus Probio-M9 (Probio-M9), against mammary cancer in mice. Thirty-six female mice were randomly divided into three groups (n = 12 per group): control group (without tumor transplantation), model group (tumor transplantation; no probiotic administration), and probiotic group (30-day oral gavage of probiotic, started seven days before tumor transplantation). Changes in tumor size was recorded, and blood, tumor tissue, and stool samples were collected at the end of the trial for analysis. Significantly smaller tumor volume was observed in the probiotic group compared with the model group (P < 0.05). Probio-M9 significantly increased the Shannon diversity index of mouse fecal microbiota and modified the gut microbiota structure (P < 0.05), characterized by significantly more Alistipes sp., Porphyromonadaceae bacterium, and Bacteroidales bacterium (P < 0.05), compared with the model group. Additionally, Probio-M9 administration elevated the serum IFN-γ, IL-9, IL-13, and IL-27 levels, while reducing the serum levels of IL-5 (P < 0.05) and several metabolites (e.g., pyridoxal, nicotinic acid, 3-hydroxybutyric acid, glutamine; P < 0.05). These physiological changes might be associated with the protective effect of Probio-M9 against mammary tumor growth. Our results support that probiotic administration could be a means of harnessing host gut microbiome and other physiological responses in combating cancer.

show abstract

“…Altogether, these data point out a possible role of managing the microbiome to provide novel leverage on breast cancer. These strategic considerations encompass the use of prebiotics [36], probiotics [37][38][39][40][41][42][43][44][45], diverse nutrition [46][47][48][49], and the careful use antibiotics to reduce the risk for breast cancer incidence and recurrence [22][23][24][25][26][27][28][29][30][31][32][33].…”

Section: Discussionmentioning

confidence: 99%

“…The causative role of oncobiosis in the pathogenesis of breast cancer is underscored by the observations that antibiotic use increases the risk for breast cancer in mice [22][23][24], and the majority of studies suggest an increased risk in humans, also [25][26][27][28][29][30][31][32][33] (it should be noted that [34] and [35] found no association between antibiotic exposure and breast cancer risk). In further support of the pathological role of the microbiome, prebiotics [36], probiotics [37][38][39][40][41][42][43][44][45], and diverse nutrition [46][47][48][49] reduce the risk of breast cancer. Furthermore, risk factors of breast cancer, such as high-density breast [50], early menarche [51], low physical activity [51], increases in BMI [51,52], age [53], and alcohol consumption [54], are also associated with microbiome changes culminating in breast cancer-associated oncobiosis.…”

Section: Oncobiosis In Breast Cancermentioning

confidence: 99%

“…As noted earlier, risk factors for breast cancer lead to decreases in diversity, such as high-density breast [ 50 ], early menarche [ 51 ], low physical activity [ 51 ], and increases in BMI [ 51 , 52 ]. Furthermore, antibiotic overdose, which leads to lower diversity, increases the risk for breast cancer [ 22 , 23 , 25 – 32 ], while probiotics that increase diversity have a protective effect [ 37 – 45 ].…”

Section: Interactions Between the Oncobiome Tumors And Tumor Cellsmentioning

confidence: 99%

See 1 more Smart Citation

The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer

Kovàcs

Mikó

Ujlaki

et al. 2021

Cancer Metastasis Rev

View full text Add to dashboard Cite

Breast cancer, the most frequent cancer in women, is characterized by pathological changes to the microbiome of breast tissue, the tumor, the gut, and the urinary tract. Changes to the microbiome are determined by the stage, grade, origin (NST/lobular), and receptor status of the tumor. This year is the 50th anniversary of when Hill and colleagues first showed that changes to the gut microbiome can support breast cancer growth, namely that the oncobiome can reactivate excreted estrogens. The currently available human and murine data suggest that oncobiosis is not a cause of breast cancer, but can support its growth. Furthermore, preexisting dysbiosis and the predisposition to cancer are transplantable. The breast’s and breast cancer’s inherent microbiome and the gut microbiome promote breast cancer growth by reactivating estrogens, rearranging cancer cell metabolism, bringing about a more inflammatory microenvironment, and reducing the number of tumor-infiltrating lymphocytes. Furthermore, the gut microbiome can produce cytostatic metabolites, the production of which decreases or blunts breast cancer. The role of oncobiosis in the urinary tract is largely uncharted. Oncobiosis in breast cancer supports invasion, metastasis, and recurrence by supporting cellular movement, epithelial-to-mesenchymal transition, cancer stem cell function, and diapedesis. Finally, the oncobiome can modify the pharmacokinetics of chemotherapeutic drugs. The microbiome provides novel leverage on breast cancer that should be exploited for better management of the disease.

show abstract

Probiotics for Prophylaxis and Management of Breast Cancer: Preclinical and Clinical Evidence

Cited by 5 publications

References 113 publications

Lacticaseibacillus rhamnosus Probio-M9-Driven Mouse Mammary Tumor-Inhibitory Effect Is Accompanied by Modulation of Host Gut Microbiota, Immunity, and Serum Metabolome

Lacticaseibacillus rhamnosus Probio-M9-Driven Mouse Mammary Tumor-Inhibitory Effect Is Accompanied by Modulation of Host Gut Microbiota, Immunity, and Serum Metabolome

Lacticaseibacillus rhamnosus Probio-M9-driven mouse mammary tumor-inhibitory effect is accompanied by modulation of host gut microbiota, immunity, and serum metabolome

The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer

Contact Info

Product

Resources

About